Using sophisticated detection methods, researchers at the Saint Louis University Institute for Molecular Virology (IMV) have demonstrated the molecular mechanism by which the HIV virus infects, or integrates, healthy cells. The discovery could lead to new drug treatments for HIV.
Although scientists theorized that two ends of the virus' DNA must come together inside a healthy cell in order to infect it, until now, investigators have not been able to illuminate the process.
"Many biological and structural aspects of HIV integration are undefined," said Sibes Bera, Ph.D. "Therefore, any insight into the molecular mechanism of this process is significant in developing integrase inhibitors."
Integrase, which was discovered by SLU researchers in 1978, is one of three HIV proteins crucial to the infection's survival. The first protein, reverse transcriptase, converts the ribonucleic acid (RNA) in HIV into deoxyribonucleic acid (DNA).
Integrase then inserts the HIV DNA into the immune cell's DNA, making it a permanent part of the cell. The third protein, protease, processes viral proteins and is essential to make infectious virus.
Drugs such as AZT and drug combinations (cocktails) exist to inhibit reverse transcriptase and protease. As of yet, there are no drugs to counter integrase.
By using a biophysical methodology known as Fluorescence Resonance Energy Transfer, Bera and his colleagues showed that the integrase holds the two ends of the viral DNA together prior to integration. Once inside the cell, the two viral DNA ends are fused by the integrase to the cell's chromosome. The integrated viral DNA allows virus replication. If the two ends of the viral DNA do not come together, infection does not take place. Millions of HIV tainted cells can be launched from a single infected cell.
"We will use this technique in our ongoing studies of the effects of drugs in the process of assembly and disassembly of the viral DNA integrase complexes," Bera said.
Source: Saint Louis University
Related stories:
New class of drug offers hope to treatment-resistant AIDS patients
For the estimated millions of AIDS patients worldwide who are resistant or are developing resistance to currently available medicines, a discovery by a University of Georgia researcher may offer a new treatment option by targeting a previously elusive enzyme in the complex retrovirus responsible for the devastating disease.
New AIDS drug shows 'phenomenal' results
AIDS researchers said a new drug shows promise for inhibiting the HIV virus in patients new to treatment or those currently taking a drug cocktail.
Study: Cells have a natural defense against HIV
Scientists here have discovered a previously unknown mechanism that cells use to fight off the human immunodeficiency virus (HIV), the cause of AIDS. The findings indicate that two proteins that normally help repair cellular DNA can also destroy the DNA made by HIV after it enters a human cell. This HIV DNA is essential for the virus to survive and reproduce.
Chemical liberated by leaky gut may allow HIV to infect the brain
In up to 20 percent of people infected with HIV, the virus manages to escape from the bloodstream and cross into the brain, resulting in HIV-associated dementia and other cognitive disorders. Now, scientists at the Albert Einstein College of Medicine of Yeshiva University have found strong evidence that a component of the cell walls of intestinal bacteria—a chemical present in high levels in the blood of HIV-infected people—helps HIV to penetrate the usually-impregnable blood brain barrier (BBB). The findings, published in the August issue of the
Journal of Virology, could lead to strategies for preventing HIV from entering the brain and causing serious complications.
Researchers discover technology that silences genes
Mount Sinai researchers have developed a new gene silencing technology that could be used to target genes that can lead to the development of certain diseases. This technology could pave the way for preventing diseases where gene dysfunction plays a role.
Viral recombination another way HIV fools the immune system
When individuals infected with HIV become infected with a second strain of the virus, the two viral strains can exchange genetic information, creating a third, recombinant strain of the virus. It is known that the presence of multiple viral strains, called superinfection, frequently leads to a loss of immune control of viral levels. Now a study from the Partners AIDS Research Center at Massachusetts General Hospital (PARC/MGH) shows that how and where viral strains swap DNA may be determined by the immune response against the original infecting strain. Their report will appear in the
Journal of Experimental Medicine and has been released online.
Natural selection may not produce the best organisms
"Survival of the fittest" is the catch phrase of evolution by natural selection. While natural selection favors the most fit organisms around, evolutionary biologists have long wondered whether this leads to the best possible organisms in the long run.
NIAID will not move forward with the PAVE 100 HIV Vaccine Trial
After soliciting and considering broad input from the scientific and HIV advocacy communities, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has determined that it will not conduct the HIV vaccine study known as PAVE 100.